Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 19, Issue 11, 2017, Pages 1630-1634

  Cusi, Kenneth ^a   Sanyal, Arun J ^b   Zhang, Shuyu ^c   Hartman, Mark L ^c   Bue Valleskey, Juliana M ^c   Hoogwerf, Byron J ^c   Haupt, Axel ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

insulin therapy; non alcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN PEGLISPRO; TRIACYLGLYCEROL; URATE; ANTIDIABETIC AGENT; INSULIN; INSULIN LISPRO; INSULIN, POLYETHYLENE GLYCOL(B1)-; MACROGOL DERIVATIVE;

ADULT; AGE; ARTICLE; BODY MASS; BODY WEIGHT; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEPATOBILIARY PARAMETERS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PREVALENCE; AGED; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECT; LIPID METABOLISM; LIVER; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN LISPRO; LIPID METABOLISM; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYETHYLENE GLYCOLS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 85021214405     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12973     Document Type: Article

References (20)

1. Doycheva I, Cui J, Nguyen P, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83-95.
2. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;178:38-45.
3. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
5. Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607.
6. Targher G, Mantovani A, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37:1729-1736.
7. Petit JM, Pedro L, Guiu B, et al. Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis. Diabet Med. 2015;32:1648-1651.
8. Llauradó G, Sevastianova K, Sadevirta S, et al. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J Clin Endocrinol Metab. 2015;100:607-616.
9. Jacober SJ, Prince MJ, Beals JM, et al. Basal insulin peglispro: overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action. Diabetes Obes Metab. 2016;18(suppl 2):3-16.
10. Bergenstal RM, Lunt H, Franek E, et al. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab. 2016;18:1081-1088.
11. Buse JB, Rodbard HW, Trescoli SC, et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39:92-100.
12. Davies MJ, Russell-Jones D, Selam JL, et al. Basal insulin peglispro versus insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab. 2016;18:1055-1064.
13. Garg S, Dreyer M, Jinnouchi H, et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Diabetes Obes Metab. 2016;18:25-33.
14. Cusi K, Sanyal AJ, Zhang S, et al. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes Metab. 2016;18:50-58.
15. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462-E468.
16. Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E829-E835.
17. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-725.
18. Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015;35:2139-2146.
19. Stadler M, Bollow E, Fritsch M, et al. Prevalence of elevated liver enzymes in adults with type 1 diabetes: a multicenter analysis of the German/Austrian DPV database. Diabetes Obes Metab. 2017;19(8):1171-1178.
20. Calanna S, Scicali R, Di Pino A, et al. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014;24:670-676.